Tamara Rordorf
Cetuximab induced aseptic meningitis.
Ulrich A, Weiler S, Weller M, Rordorf T, Tarnutzer A. Cetuximab induced aseptic meningitis. J Clin Neurosci 2015; 22:1061-3.
11.03.2015Cetuximab induced aseptic meningitis.
11.03.2015J Clin Neurosci 2015; 22:1061-3
Ulrich A, Weiler S, Weller M, Rordorf Tamara, Tarnutzer A A
Uncommon case of brain metastasis in a patient with a history of heavy smoking.
Scharl M, Bode B, Rushing E, Knuth A, Rordorf T. Uncommon case of brain metastasis in a patient with a history of heavy smoking. Curr Oncol 2014; 21:e728-31.
01.10.2014Uncommon case of brain metastasis in a patient with a history of heavy smoking.
01.10.2014Curr Oncol 2014; 21:e728-31
Scharl Michael, Bode B, Rushing Elisabeth Jane, Knuth A, Rordorf Tamara
Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.
Rordorf T, Hassan A, Azim H, Alexandru E, Er O, Gokmen E, Güral Z, Mardiak J, Minchev V, Peintinger F, Szendroi M, Takac I, Tesarova P, Vorobiof D, Vrbanec D, Yildiz R, Yücel S, Zekri J, Oyan B, Swiss Group for Clinical Cancer Research (SAKK). Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup. Breast 2014; 23:511-25.
27.06.2014Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.
27.06.2014Breast 2014; 23:511-25
Rordorf Tamara, Hassan Azza Adel, Azim Hamdy, Alexandru Eniu, Er Ozlem, Gokmen Erhan, Güral Zeynep, Mardiak Jozef, Minchev Velko, Peintinger Florentia, Szendroi Miklos, Takac Itzok, Tesarova Petra, Vorobiof Daniel, Vrbanec Damir, Yildiz Ramazan, Yücel Serap, Zekri Jamal, Oyan Basak, Swiss Group for Clinical Cancer Research (SAKK)
Late term tolerance in head neck cancer patients irradiated in the IMRT era.
Studer G, Linsenmeier C, Riesterer O, Najafi Y, Brown M, Yousefi B, Bredell M, Huber G, Schmid S, Studer S, Zwahlen R, Rordorf T, Glanzmann C. Late term tolerance in head neck cancer patients irradiated in the IMRT era. Radiat Oncol 2013; 8:259.
05.11.2013Late term tolerance in head neck cancer patients irradiated in the IMRT era.
05.11.2013Radiat Oncol 2013; 8:259
Studer Gabriela, Linsenmeier Claudia, Riesterer Oliver, Najafi Yousef, Brown Michelle L, Yousefi Bita, Bredell Marius, Huber Gerhard, Schmid Stephan, Studer Stephan, Zwahlen Roger A, Rordorf Tamara, Glanzmann Christoph
Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.
Anghel R, Bachmann A, Beksac M, Brodowicz T, Finek J, Komadina R, Krzemieniecki K, Láng I, Marencak J, von Moos R, Pecherstorfer M, Rordorf T, Vrbanec D, Zielinski C. Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease. Wien Klin Wochenschr 2013; 125:439-47.
06.07.2013Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.
06.07.2013Wien Klin Wochenschr 2013; 125:439-47
Anghel Rodica, Bachmann Alexander, Beksac Meral, Brodowicz Thomas, Finek Jindřich, Komadina Radko, Krzemieniecki Krzysztof, Láng István, Marencak Jozef, von Moos Roger, Pecherstorfer Martin, Rordorf Tamara, Vrbanec Damir, Zielinski Christoph C
Treatment concepts of oral cancer.
Bredell M, Rordorf T, Studer G. Treatment concepts of oral cancer. SADJ 2012; 67:574-6.
01.11.2012Treatment concepts of oral cancer.
01.11.2012SADJ 2012; 67:574-6
Bredell M G, Rordorf Tamara, Studer G
Follow up after IMRT in oral cavity cancer: update.
Studer G, Brown M, Bredell M, Graetz K, Huber G, Linsenmeier C, Najafi Y, Riesterer O, Rordorf T, Schmid S, Glanzmann C. Follow up after IMRT in oral cavity cancer: update. Radiat Oncol 2012; 7:84.
11.06.2012Follow up after IMRT in oral cavity cancer: update.
11.06.2012Radiat Oncol 2012; 7:84
Studer Gabriela, Brown Michelle L, Bredell Marius, Graetz Klaus W, Huber Gerhard, Linsenmeier Claudia, Najafi Yousef, Riesterer Oliver, Rordorf Tamara, Schmid Stephan, Glanzmann Christoph
Impact of tumor volume and systemic therapy on outcome in patients undergoing IMRT for large volume head neck cancer.
Studer G, Rordorf T, Glanzmann C. Impact of tumor volume and systemic therapy on outcome in patients undergoing IMRT for large volume head neck cancer. Radiat Oncol 2011; 6:120.
22.09.2011Impact of tumor volume and systemic therapy on outcome in patients undergoing IMRT for large volume head neck cancer.
22.09.2011Radiat Oncol 2011; 6:120
Studer Gabriela, Rordorf Tamara, Glanzmann Christoph
123I-Methyljodbenzylguanidin- (MIBG-) Szintigraphie: Paradoxe Nuklidspeicherung eines onkozytären Nebennierenrindenkarzinoms.
Padberg B, Rordorf T, Suter S, Pfeiffer D, Wild D, Schröder S. 123I-Methyljodbenzylguanidin- (MIBG-) Szintigraphie: Paradoxe Nuklidspeicherung eines onkozytären Nebennierenrindenkarzinoms. Pathologe 2007; 28:281-4.
01.07.2007123I-Methyljodbenzylguanidin- (MIBG-) Szintigraphie: Paradoxe Nuklidspeicherung eines onkozytären Nebennierenrindenkarzinoms.
01.07.2007Pathologe 2007; 28:281-4
Padberg B-C, Rordorf Tamara, Suter S, Pfeiffer D, Wild D, Schröder Stephan
Undifferentiated sarcoma arising in the brain, 23 years after curative treatment of an ependymoma.
Hofer S, Seeger H, Rordorf T, Knuth A, Janzer R. Undifferentiated sarcoma arising in the brain, 23 years after curative treatment of an ependymoma. J Neurooncol 2005; 72:239.
01.05.2005Undifferentiated sarcoma arising in the brain, 23 years after curative treatment of an ependymoma.
01.05.2005J Neurooncol 2005; 72:239
Hofer Silvia, Seeger Harald, Rordorf Tamara, Knuth Alexander, Janzer Robert
Streptobacillus moniliformis endocarditis in an HIV-positive patient.
Rordorf T, Züger C, Zbinden R, von Graevenitz A, Pirovino M. Streptobacillus moniliformis endocarditis in an HIV-positive patient. Infection 2000; 28:393-4.
01.01.2000Streptobacillus moniliformis endocarditis in an HIV-positive patient.
01.01.2000Infection 2000; 28:393-4
Rordorf Tamara, Züger C, Zbinden R, von Graevenitz A, Pirovino Mauro
Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit.
Yu J, Zhang Y, McIlroy J, Rordorf T, Orr G, Backer J. Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 1998; 18:1379-87.
01.03.1998Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit.
01.03.1998Mol Cell Biol 1998; 18:1379-87
Yu J, Zhang Yan, McIlroy J, Rordorf Tamara, Orr G A, Backer J M
Central versus peripheral site of action of the tachykinin NK1-antagonist RP 67580 in inhibiting chemonociception.
Holzer-Petsche U, Rordorf T. Central versus peripheral site of action of the tachykinin NK1-antagonist RP 67580 in inhibiting chemonociception. Br J Pharmacol 1995; 115:486-90.
01.06.1995Central versus peripheral site of action of the tachykinin NK1-antagonist RP 67580 in inhibiting chemonociception.
01.06.1995Br J Pharmacol 1995; 115:486-90
Holzer-Petsche U, Rordorf Tamara
Regulation of phosphatidylinositol 3'-kinase by tyrosyl phosphoproteins. Full activation requires occupancy of both SH2 domains in the 85-kDa regulatory subunit.
Rordorf T, Van Horn D, Chen D, White M, Backer J. Regulation of phosphatidylinositol 3'-kinase by tyrosyl phosphoproteins. Full activation requires occupancy of both SH2 domains in the 85-kDa regulatory subunit. J Biol Chem 1995; 270:3662-6.
24.02.1995Regulation of phosphatidylinositol 3'-kinase by tyrosyl phosphoproteins. Full activation requires occupancy of both SH2 domains in the 85-kDa regulatory subunit.
24.02.1995J Biol Chem 1995; 270:3662-6
Rordorf Tamara, Van Horn D J, Chen D C, White M F, Backer J M